HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

Abstract

Highly active antiretroviral therapy (HAART) results in potent and durable suppression of HIV-1 viremia. However, HIV-1 replication resumes if therapy is interrupted1,2. Although it is generally believed that active replication has been halted in individuals on HAART, immune activation and inflammation continue at abnormal levels3, suggesting continued, low-level viral replication. To assess whether active replication might be driving immune activation in HAART, we examined the impact of treatment intensification with the integrase inhibitor raltegravir on viral complementary DNA and immune activation parameters. In the presence of raltegravir, linear HIV-1 cDNA is prevented from integrating into chromatin and is subsequently converted to episomal cDNAs4,5. Raltegravir intensification of a three-drug suppressive HAART regimen resulted in a specific and transient increase in episomal DNAs in a large percentage of HAART-suppressed subjects. Furthermore, in subjects with these episomal DNAs, immune activation was higher at baseline and was subsequently normalized after raltegravir intensification. These results suggest that, despite suppressive HAART, active replication persists in some infected individuals and drives immune activation. The ability of raltegravir intensification to perturb the reservoir that supports active replication has implications for therapeutic strategies aimed at achieving viral eradication.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Impact of raltegravir intensification on HIV-1 2-LTR circles in HAART-suppressed subjects.
Figure 2: Changes in total and integrated HIV-1 DNA.
Figure 3: Phenotypic analysis of lymphocyte subsets in subjects treated with raltegravir after stratification on the basis of 2-LTR positivity (2-LTR+) and negativity (2-LTR), as assessed in fresh blood samples by multicolor flow cytometry at weeks 0, 2, 4, 12 and 24.

References

  1. 1

    Davey, R.T. Jr. et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Natl. Acad. Sci. USA 96, 15109–15114 (1999).

  2. 2

    Markowitz, M. et al. Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J. Infect. Dis. 186, 634–643 (2002).

  3. 3

    Jiang, W. et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J. Infect. Dis. 199, 1177–1185 (2009).

  4. 4

    Middleton, T. et al. Inhibition of human immunodeficiency virus type I integrase by naphthamidines and 2-aminobenzimidazoles. Antiviral Res. 64, 35–45 (2004).

  5. 5

    Svarovskaia, E.S. et al. Azido-containing diketo acid derivatives inhibit human immunodeficiency virus type 1 integrase in vivo and influence the frequency of deletions at two-long-terminal-repeat-circle junctions. J. Virol. 78, 3210–3222 (2004).

  6. 6

    Perelson, A.S. et al. Decay characteristics of HIV-1–infected compartments during combination therapy. Nature 387, 188–191 (1997).

  7. 7

    Bailey, J.R. et al. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J. Virol. 80, 6441–6457 (2006).

  8. 8

    Joos, B. et al. HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc. Natl. Acad. Sci. USA 105, 16725–16730 (2008).

  9. 9

    Kieffer, T.L. et al. Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J. Infect. Dis. 189, 1452–1465 (2004).

  10. 10

    Parera, M., Ibanez, A., Clotet, B. & Martinez, M.A. Lack of evidence for protease evolution in HIV-1–infected patients after 2 years of successful highly active antiretroviral therapy. J. Infect. Dis. 189, 1444–1451 (2004).

  11. 11

    Sedaghat, A.R., Siliciano, J.D., Brennan, T.P., Wilke, C.O. & Siliciano, R.F. Limits on replenishment of the resting CD4+ T cell reservoir for HIV in patients on HAART. PLoS Pathog. 3, e122 (2007).

  12. 12

    Peterson, S., Reid, A.P., Kim, S. & Siliciano, R.F. Treatment implications of the latent reservoir for HIV-1. Adv. Pharmacol. 55, 411–425 (2007).

  13. 13

    Chun, T.W. et al. Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection. Proc. Natl. Acad. Sci. USA 95, 8869–8873 (1998).

  14. 14

    Chun, T.W. et al. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J. Infect. Dis. 195, 1762–1764 (2007).

  15. 15

    Chun, T.W. et al. HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J. Clin. Invest. 115, 3250–3255 (2005).

  16. 16

    Günthard, H.F. et al. Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. J. Virol. 73, 9404–9412 (1999).

  17. 17

    Martínez, M.A. et al. Human immunodeficiency virus type 1 genetic evolution in patients with prolonged suppression of plasma viremia. Virology 256, 180–187 (1999).

  18. 18

    Martinez-Picado, J. et al. Viral evolution during structured treatment interruptions in chronically human immunodeficiency virus–infected individuals. J. Virol. 76, 12344–12348 (2002).

  19. 19

    Ramratnam, B. et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat. Med. 6, 82–85 (2000).

  20. 20

    Sharkey, M., Triques, K., Kuritzkes, D.R. & Stevenson, M. In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA. J. Virol. 79, 5203–5210 (2005).

  21. 21

    Sharkey, M.E. et al. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat. Med. 6, 76–81 (2000).

  22. 22

    Havlir, D.V. et al. Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1–infected persons treated with suppressive antiretroviral therapy for five years. J. Virol. 77, 11212–11219 (2003).

  23. 23

    Palmer, S. et al. New real-time reverse transcriptase–initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J. Clin. Microbiol. 41, 4531–4536 (2003).

  24. 24

    Palmer, S. et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc. Natl. Acad. Sci. USA 105, 3879–3884 (2008).

  25. 25

    Catalfamo, M. et al. HIV infection-associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells. Proc. Natl. Acad. Sci. USA 105, 19851–19856 (2008).

  26. 26

    Kolber, M.A. et al. Intensification of a suppressive HAART regimen increases CD4 counts and decreases CD8+ T-cell activation. Clin. Immunol. 126, 315–321 (2008).

  27. 27

    Hunt, P.W. et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J. Infect. Dis. 187, 1534–1543 (2003).

  28. 28

    Brenchley, J.M. et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12, 1365–1371 (2006).

  29. 29

    Bourgeois, C., Hao, Z., Rajewsky, K., Potocnik, A.J. & Stockinger, B. Ablation of thymic export causes accelerated decay of naive CD4 T cells in the periphery because of activation by environmental antigen. Proc. Natl. Acad. Sci. USA 105, 8691–8696 (2008).

  30. 30

    Giorgi, J.V. et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J. Infect. Dis. 179, 859–870 (1999).

  31. 31

    Liu, Z. et al. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 16, 83–92 (1997).

  32. 32

    Brussel, A. & Sonigo, P. Analysis of early human immunodeficiency virus type 1 DNA synthesis by use of a new sensitive assay for quantifying integrated provirus. J. Virol. 77, 10119–10124 (2003).

Download references

Acknowledgements

We are grateful to the Integral study group members R. Escrig, M. Larús, I. Bravo and J. Puig for clinical monitoring during the study and to R. Ayén, T. González and E. Grau for sample processing. We thank N. Hosoya and D.R. Kuritzkes (Massachusetts General Hospital, Boston) for providing the plasmid to generate the standard for the integrated HIV-1 DNA quantification. We wish to thank the volunteers who participated in this study. This study was supported by the Spanish AIDS network 'Red Temática Cooperativa de Investigación en SIDA' (RD06/0006), by funding from the European Community's Seventh Framework Program (FP7/2007-2013) under the Collaborative HIV and Anti-HIV Drug Resistance Network grant agreement 223131, by funding from the US National Institutes of Health to M. Stevenson and by an unrestricted grant from Merck Sharp & Dohme. J.B. is a researcher from Fundació Institut de Recerca en Ciències de la Salut Germans Trias i Pujol supported by the Instituto de Salud Carlos III and the Health Department of the Catalan Government (Generalitat de Catalunya). M.J.B. and M.M. were supported by Agència de Gestió d'Ajuts Universitaris i de Recerca from Generalitat de Catalunya and the European Social Fund. M.M. is appointed to the Pompeu Fabra University PhD program. S.P. was funded, in part, by the Swedish Research Council and by 107170-44-RGRL from the Foundation for AIDS Research.

Author information

M.J.B. and M.M. designed, executed and interpreted most experiments and prepared the manuscript. J.M.L. designed the study and participated in subject recruitment and clinical care. A.E. performed statistical analyses. V.D. executed single-copy assays. M.C.P. helped with real-time PCR experiments. J.M.G. and P.D. participated in subject recruitment and clinical care. R.P. contributed in experimental design. M. Sharkey helped in experimental setup and provided reagents. S.P. executed single-copy assays. M. Stevenson provided interpretation of the data and helped with the manuscript preparation. B.C. designed the study, participated in subject recruitment and clinical care and provided interpretation of the data. J.B. supervised immunological experiments, data interpretation and participated in manuscript preparation. J.M.-P. supervised all aspects of this study including study design, execution and interpretation and manuscript preparation.

Correspondence to Javier Martinez-Picado.

Ethics declarations

Competing interests

J.M.L. has received research funding, consultancy fees or lecture sponsorships from Abbott, Boehringer-Ingelheim, Gilead Sciences, GlaxoSmithKline, Jansen-Cilag, Merck, Pfizer and Roche. R.P. has received grant support or lecture fees from Boehringer-Ingelheim, Monogram, Pfizer, Merck and Siemens Medical Solutions. M.S. has been a consultant for Merck and has received research support from Tibotec. J.M.G. has received grant support or lecture or advisory fees from Merck, Roche, GlaxoSmithKline, Bristol-Myers Squibb, Tibotec, Pfizer, Gilead, Abbott and Boehringer Ingelheim. B.C. has served as a consultant on advisory boards, participated in speakers' bureaus or conducted clinical trials with Roche, Boehringer-Ingelheim, Abbott, Bristol-Myers Squibb, GlaxoSmithKline, Gilead, Tibotec, Janssen, Merck, Pfizer, Siemens, Monogram Biosciences and Panacos. J.M.-P. has received research funding, consultancy fees, or lecture sponsorships from GlaxoSmithKline, Merck and Roche.

Supplementary information

Supplementary Text and Figures

Supplementary Figs. 1–4 and Supplementary Tables 1–4 (PDF 3087 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

J Buzón, M., Massanella, M., Llibre, J. et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 16, 460–465 (2010). https://doi.org/10.1038/nm.2111

Download citation

Further reading